Wells Fargo & Company Acelrx Pharmaceuticals Inc Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.2 - $0.35 $851 - $1,489	-4,257 Reduced 17.94%	19,478 $4,000
Q2 2022 Aug 12, 2022	BUY	$0.18 - $0.29 $600 - $966	3,334 Added 16.34%	23,735 $6,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.61 $47 - $103	170 Added 0.84%	20,401 $6,000
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $8,182 - $17,032	-16,699 Reduced 45.22%	20,231 $11,000
Q3 2021 Nov 15, 2021	SELL	$0.93 - $1.51 $5,613 - $9,114	-6,036 Reduced 14.05%	36,930 $38,000
Q2 2021 Aug 16, 2021	SELL	$1.03 - $1.7 $88,418 - $145,933	-85,843 Reduced 66.64%	42,966 $59,000
Q1 2021 May 13, 2021	SELL	$1.25 - $2.77 $234,778 - $520,269	-187,823 Reduced 59.32%	128,809 $219,000
Q4 2020 Feb 09, 2021	BUY	$1.18 - $1.98 $131,450 - $220,570	111,399 Added 54.28%	316,632 $393,000
Q3 2020 Nov 05, 2020	SELL	$1.01 - $1.81 $30,398 - $54,477	-30,098 Reduced 12.79%	205,233 $291,000
Q2 2020 Aug 13, 2020	BUY	$1.03 - $1.69 $20,107 - $32,992	19,522 Added 9.05%	235,331 $285,000
Q1 2020 May 14, 2020	BUY	$0.76 - $2.07 $164,014 - $446,724	215,809 New	215,809 $255,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.